OnTrackCF: Engagement, Feasibility, and Acceptability Study

Key facts

Sponsor

Boston Children's Hospital

Principal Investigator

Kristin Riekert, PhD

Johns Hopkins University

Intervention

OnTrackCF(behavioral)

Enrollment

60 target

Eligibility

18 years · All sexes

Timeline

2025 – 2026

Study locations (3)

• University of Alabama-Birmingham, Birmingham, Alabama, United States
• Johns Hopkins University, Baltimore, Maryland, United States
• Boston Children's Hospital, Boston, Massachusetts, United States

Collaborators

Cystic Fibrosis Foundation · Johns Hopkins University · University of Alabama at Birmingham

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Cystic fibrosis-gastritis-megaloblastic anemia syndrome

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07071324
  CF Wellness Program
  Johns Hopkins University
• RECRUITINGNANCT07223255
  Gastrointestinal Response of Pediatric Cystic Fibrosis Patients on Mediterranean Diet
  Dartmouth-Hitchcock Medical Center
• ACTIVE NOT RECRUITINGNCT07147803
  Sleep Quality in Patients With Non-cystic Fibrosis Bronchiectasis
  Assiut University
• RECRUITINGPHASE2NCT06998043
  Study With Phage for CF Subjects With Pseudomonas Lung Infection
  BiomX Ltd
• RECRUITINGNCT06683092
  Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)
  Boston Children's Hospital
• RECRUITINGPHASE2NCT06559150
  A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis
  Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
• RECRUITINGPHASE4NCT05704036
  Estrogen Supplementation and Bone Health in Women With CF
  Johns Hopkins University
• RECRUITINGNCT06274840
  COVID-19 Antibody Responses In Cystic Fibrosis
  Pilar Azevedo

See all trials for Cystic fibrosis-gastritis-megaloblastic anemia syndrome →